Sorafenib in Urothelium Cancer of Bladder

NCT01215266 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

98

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment

Conditions

Bladder Cancer

Interventions

DRUG: Sorafenib
DRUG: Placebo

Sponsor

Association of Urologic Oncology (AUO)

Collaborators

[object Object]